SCHEMBL7934111

SCHEMBL7934111

Nc1ncccc1NCc1cc(NC(=O)c2oc3ccc(Br)cc3c2N)ccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.44
NPC1 O15118 5/20 0.44
BACE1 P56817 6/20 0.44
MAPT P10636 2/20 0.40
ADORA2A P29274 1/20 0.40
CASP1 P29466 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 2/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
NFKB1 P19838 1/20 0.39
HTT P42858 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
TP53 P04637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
AURKA O14965 1/20 0.38
AURKB Q96GD4 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7944704 0.93 RAB9A (0.54) RAB9ANPC1BACE1MAPTSMN1; SMN2
SCHEMBL7934104 0.85 RAB9A (0.47) RAB9ANPC1BACE1MAPTADORA2A
SCHEMBL7945232 0.85 BACE1 (0.53) RAB9ANPC1BACE1MAPTADORA2A
SCHEMBL7941526 0.85 RAB9A (0.52) RAB9ANPC1BACE1MAPTSMN1; SMN2
SCHEMBL7939899 0.84 DGAT1 (0.50) RAB9ANPC1BACE1MAPTPTGDR2
SCHEMBL7942886 0.84 DGAT1 (0.49) RAB9ANPC1BACE1MAPTSMN1; SMN2
SCHEMBL7933478 0.84 RAB9A (0.53) RAB9ANPC1MAPTSMN1; SMN2KDM4E
SCHEMBL7933483 0.83 RAB9A (0.43) RAB9ANPC1BACE1MAPTKDM4E
SCHEMBL7939895 0.83 RXFP1 (0.51) RAB9ANPC1BACE1MAPTSMN1; SMN2
SCHEMBL7945289 0.82 BACE1 (0.50) BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 RAB9A 1287/4885NPC1 431/4885BACE1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.